All Stories

  1. The Emerging Role of Prehabilitation in Kidney Transplant Candidates
  2. Diet Quality as a Determinant of kidney-related complications of diabetes and hypertension
  3. Acute Kidney Injury in Hospitalized Cancer Patients: Single-Centre Real-Life Analysis of Incidence and Clinical Impact
  4. Muscle mass and myosteatosis as predictors of outcome in kidney transplantation
  5. Dapagliflozin Mitigates Medullary Hypoxia in CKD Patients
  6. Cell Senescence in Kidney Aging and in Kidney Disease
  7. Magnetic noise mitigation for upcoming Gravitational Waves detectors
  8. Efficacy and safety of avacopan for treatment of patients with ANCA-associated vasculitis receiving cyclophosphamide
  9. Treatment With Avacopan in ANCA–Associated Vasculitis With Kidney Involvement
  10. Physical exercise in patients with chronic kidney disease: a Call to action
  11. Dietary Protein Intake Recommendations for Patients with Non-Dialysis Dependent CKD: What Should Healthcare Providers Do?
  12. Centers for nutritional care: a further step to improve healthcare quality in patients with chronic renal disease.
  13. Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trial
  14. The Discordance Between Creatinine-Based and Cystatin C-Based Estimated Glomerular Filtration Rate: A Matter of Protein Intake?
  15. The Complex Nutrition Needs of Patients With Chronic Kidney Disease and Chronic Liver Disease
  16. Saltiness perception and sodium intake in patients with chronic kidney disease
  17. Adiponectin removal by the human kidney: a preliminary study
  18. Emergence of Artificial Intelligence in Renal Nutrition Applications
  19. Future gravitational wave detectors: Phase noise investigation and magnetic noise mitigation strategies
  20. Reflecting on Remarkable Years at the Journal of Renal Nutrition: Innovation in Dietary and Nutritional Interventions in Kidney Health and Disease
  21. Cognitive Disorders in Chronic Kidney Disease: We Are What We Eat
  22. SGLT2 inhibition to target kidney aging
  23. Hypoglycemia in patients with end-stage kidney disease
  24. Altered adiponectin regulation in skeletal muscle of patients with chronic kidney disease
  25. Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial
  26. SA-β-Gal in Kidney Tubules as a Predictor of Renal Outcome in Patients with Chronic Kidney Disease
  27. Nephrological Complications in Hemoglobinopathies: SITE Good Practice
  28. Sa-β-Gal in Kidney Tubules as a Predictor of Renal Outcome in Patients with Chronic Kidney Disease
  29. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial
  30. The Contribution of Muscle Innate Immunity to Uremic Cachexia
  31. Nutritional and Dietary Management of Chronic Kidney Disease under Conservative and Preservative Kidney Care without Dialysis
  32. A Toll‐like receptor‐4/NLRP3 inflammasome pathway promotes inflammation in skeletal muscle of chronic kidney disease patients
  33. Homocysteine exchange across skeletal muscle in patients with chronic kidney disease
  34. Role of Uric Acid in Vascular Remodeling: Cytoskeleton Changes and Migration in VSMCs
  35. Treatment of Chronic Kidney Disease: Moving Forward
  36. An Updated Focus on Immune Checkpoint Inhibitors and Tubulointerstitial Nephritis
  37. Muscle atrophy in CKD: A historical perspective of advancements in its understanding.
  38. SIRPα Mediates IGF1 Receptor in Cardiomyopathy-Induced by Chronic Kidney Disease
  39. Accessing global kidney nutrition care
  40. Secondary Membranous Nephropathy Due to Benign Tumors in 2 Young Women: A Case Report
  41. Second Wave Antibodies in Autoimmune Renal Diseases: The Case of Lupus Nephritis
  42. Renal Ischemia/Reperfusion Early Induces Myostatin and PCSK9 Expression in Rat Kidneys and HK-2 Cells
  43. A Changing Perspective for Treatment of Chronic Kidney Disease
  44. Myostatin/Activin-A Signaling in the Vessel Wall and Vascular Calcification
  45. How to Overcome Anabolic Resistance in Dialysis-Treated Patients?
  46. A Comparative Analysis of Nutritional Assessment Using Global Leadership Initiative on Malnutrition Versus Subjective Global Assessment and Malnutrition Inflammation Score in Maintenance Hemodialysis Patients
  47. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease
  48. Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD
  49. Post-transplant de novo non donor-specific HLA antibodies are not associated with poor graft outcome in non-sensitized pediatric recipients of kidney transplantation
  50. Effects of Different Dialysis Strategies on Inflammatory Cytokine Profile in Maintenance Hemodialysis Patients with COVID-19: A Randomized Trial
  51. Testosterone Disorders and Male Hypogonadism in Kidney Disease
  52. Avacopan for the Treatment of ANCA-Associated Vasculitis
  53. Effects of Late Conversion from Twice-Daily to Once-Daily Slow Release Tacrolimus on the Insulin Resistance Indexes in Kidney Transplant Patients
  54. Cellular Senescence Is Associated with Faster Progression of Focal Segmental Glomerulosclerosis
  55. Risk factors and action thresholds for the novel coronavirus pandemic. Insights from the Italian Society of Nephrology COVID-19 Survey
  56. The role of uric acid in renal damage - A history of inflammatory pathways and vascular remodeling
  57. Low Protein Diets and Plant-Based Low Protein Diets: Do They Meet Protein Requirements of Patients with Chronic Kidney Disease?
  58. Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis
  59. Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part 2): prospective study
  60. Ten-Year Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant: A Prospective Cohort Study
  61. Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy
  62. Increased serum uric acid levels are associated to renal arteriolopathy and predict poor outcome in IgA nephropathy
  63. Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy
  64. Myostatin in the Arterial Wall of Patients with End-Stage Renal Disease
  65. Nutritional management of kidney diseases: an unmet need in patient care
  66. Mechanisms Regulating Muscle Protein Synthesis in Chronic Kidney Disease
  67. Successful kidney transplantation after COVID‐19
  68. New Treatment Options for Hyperkalemia in Patients with Chronic Kidney Disease
  69. The International Society of Renal Nutrition and Metabolism Commentary on the National Kidney Foundation and Academy of Nutrition and Dietetics KDOQI Clinical Practice Guideline for Nutrition in Chronic Kidney Disease
  70. Fructose and Uric Acid: Major Mediators of Cardiovascular Disease Risk Starting at Pediatric Age
  71. Everolimus for BKV nephropathy in kidney transplant recipients: a prospective, controlled study.
  72. P0915PROTEIN ENERGY WASTING IS ASSOCIATED WITH A DECLINE IN MUSCLE PROTEIN SYNTHESIS IN CKD PATIENTS
  73. Management of COVID ‐19 in hemodialysis patients: The Genoa experience
  74. Long-term blood pressure behavior and progression to end-stage renal disease in patients with immunoglobulin A nephropathy
  75. Muscle protein turnover and low-protein diets in patients with chronic kidney disease
  76. Enhanced myostatin expression and signalling promote tubulointerstitial inflammation in diabetic nephropathy
  77. Nutritional Challenges in Pregnant Women with Renal Diseases: Relevance to Fetal Outcomes
  78. Activin/myostatin receptor signaling and vascular calcifications in chronic kidney disease: A “liaison dangereuse”?
  79. Wasting and Cachexia in Chronic Kidney Disease
  80. Two-Day ABPM-Derived Indices and Mortality in Hemodialysis Patients
  81. Signal regulatory protein alpha initiates cachexia through muscle to adipose tissue crosstalk
  82. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups
  83. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
  84. FO052MYOSTATIN PROMOTES TUBULAR INFLAMMATION IN DIABETIC NEPHROPATHY
  85. SP379BIOACTIVE MOLECULES EXTRACTED FROM OLIVE POMACE PROTECT SKELETAL MUSCLE CELLS FROM UREMIC INFLAMMATION
  86. Early interstitial macrophage infiltration with mild dysfunction is associated with subsequent kidney graft loss
  87. Neutrophil Extracellular Traps Profiles in Patients with Incident Systemic Lupus Erythematosus and Lupus Nephritis
  88. Indoxyl Sulfate Induces Renal Fibroblast Activation through a Targetable Heat Shock Protein 90-Dependent Pathway
  89. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Randomized Controlled Study
  90. Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial
  91. Emerging role of myostatin and its inhibition in the setting of chronic kidney disease
  92. The Organ Handling of Soluble Klotho in Humans
  93. Immunohistochemical Staining of TLR4 in Human Skeletal Muscle Samples
  94. Uric acid and angiotensin II additively promote inflammation and oxidative stress in human proximal tubule cells by activation of toll‐like receptor 4
  95. Testosterone deficiency, frailty and muscle wasting in CKD: a converging paradigm?
  96. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study
  97. Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs: An Observational Prospective Multicenter Study
  98. Soluble Toll-like Receptor 4: A New Player in Subclinical Inflammation and Malnutrition in Hemodialysis Patients
  99. Nutritional treatment of advanced CKD: twenty consensus statements
  100. FP304WASTING IN PATIENTS WITH CKD AND DIABETES: THE ROLE OF MYOSTATIN
  101. Effects of Low-Protein, and Supplemented Very Low–Protein Diets, on Muscle Protein Turnover in Patients With CKD
  102. The contribution of muscle, kidney, and splanchnic tissues to leucine transamination in humans
  103. Eating During Hemodialysis Treatment: A Consensus Statement From the International Society of Renal Nutrition and Metabolism
  104. Toll-like receptor-4 signaling mediates inflammation and tissue injury in diabetic nephropathy
  105. The nuclear phosphatase SCP4 regulates FoxO transcription factors during muscle wasting in chronic kidney disease
  106. Myostatin mediates abdominal aortic atherosclerosis progression by inducing vascular smooth muscle cell dysfunction and monocyte recruitment
  107. Glutamine Transport and Metabolism in Cancer
  108. Glutamine Supplementation in Critical Illness
  109. Interorgan handling of fibroblast growth factor-23 in humans
  110. Modulation of Myostatin/Hepatocyte Growth Factor Balance by Different Hemodialysis Modalities
  111. De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients
  112. Toll-like receptor 4 signalling mediates inflammation in skeletal muscle of patients with chronic kidney disease
  113. Kidney Intragraft Homing ofDe NovoDonor-Specific HLA Antibodies Is an Essential Step of Antibody-Mediated Damage but NotPer SePredictive of Graft Loss
  114. Low-protein diets for chronic kidney disease patients: the Italian experience
  115. Studying Muscle Protein Turnover in CKD
  116. Peripheral artery disease and blood pressure profile abnormalities in hemodialysis patients
  117. Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients
  118. Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response
  119. Insulin sensitivity of muscle protein metabolism is altered in patients with chronic kidney disease and metabolic acidosis
  120. Gene expression in highly sensitized dialysis patients waiting for a kidney transplant: A real-time PCR analysis
  121. Regression of asymptomatic cardiomyopathy and clinical outcome of renal transplant recipients: a long-term prospective cohort study
  122. FP776EFFECTS OF DIALYSIS MODALITY ON MYOSTATIN/HGF BALANCE IN REGULAR HD PATIENTS
  123. Uric Acid Promotes Apoptosis in Human Proximal Tubule Cells by Oxidative Stress and the Activation of NADPH Oxidase NOX 4
  124. Enhanced glomerular Toll-like receptor 4 expression and signaling in patients with type 2 diabetic nephropathy and microalbuminuria
  125. Effect of protein-energy wasting (PEW) on muscle protein metabolism and oxygen consumption in patients with end-stage renal disease (ESRD)
  126. Effects of peritoneal dialysis on protein metabolism
  127. Stat3 Activation Links a C/EBPδ to Myostatin Pathway to Stimulate Loss of Muscle Mass
  128. Risk factors for kidney diseases and awareness of blood pressure and proteinuria in general population and in high school students: Italian report for World Kidney Days 2012-2013
  129. 1,25-Dihydroxy vitamin D and coronary microvascular function
  130. PosttransplantDe NovoDonor-Specific HLA Antibodies Identify Pediatric Kidney Recipients at Risk for Late Antibody-Mediated Rejection
  131. Lysine triggers apoptosis through a NADPH oxidase-dependent mechanism in human renal tubular cells
  132. Awareness of kidney diseases in general population and in high school students. Italian report for World Kidney Days 2010-2011
  133. Effect of kidney failure and hemodialysis on protein and amino acid metabolism
  134. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up
  135. Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens
  136. Protein-Energy Wasting and Mortality in Chronic Kidney Disease
  137. Evaluation of Metabolic Acidosis in Patients With a Kidney Graft: Comparison of the Bicarbonate-Based and Strong Ion–Based Methods
  138. Apoptosis and myostatin mRNA are upregulated in the skeletal muscle of patients with chronic kidney disease
  139. The human kidney as a regulator of body cytokine homeostasis
  140. Amino Acid Biosynthesis
  141. Pregnancy and Progression of IgA Nephropathy: Results of an Italian Multicenter Study
  142. Amino acid and protein metabolism in the human kidney and in patients with chronic kidney disease
  143. Effects of Chronic Metabolic Acidosis on Splanchnic Protein Turnover and Oxygen Consumption in Human Beings
  144. Androgen-mediated apoptosis of kidney tubule cells: Role of c-Jun amino terminal kinase
  145. The kidney is the major site of S-adenosylhomocysteine disposal in humans
  146. Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody—Associated Vasculitis
  147. Mechanisms of renal ammonia production and protein turnover
  148. Accelerated senescence in the kidneys of patients with type 2 diabetic nephropathy
  149. Effects of uremia and inflammation on growth hormone resistance in patients with chronic kidney diseases
  150. Elevated serum levels of S-adenosylhomocysteine, but not homocysteine, are associated with cardiovascular disease in stage 5 chronic kidney disease patients
  151. Response to ‘Renal microvascular and tubular injuries in type II diabetic nephropathy’
  152. In Reply
  153. Apoptosis in the kidneys of patients with type II diabetic nephropathy
  154. Efficacy and Safety of a Very-Low-Protein Diet When Postponing Dialysis in the Elderly: A Prospective Randomized Multicenter Controlled Study
  155. Current structure and organization for renal patient assistance in Italy
  156. Kidney and splanchnic handling of Interleukin-6 in humans
  157. Peripheral tissue release of interleukin-6 in patients with chronic kidney diseases: Effects of end-stage renal disease and microinflammatory state
  158. Causes of Hyperhomocysteinemia in Patients With Chronic Kidney Diseases
  159. Effects of Insulin on Methionine and Homocysteine Kinetics in Type 2 Diabetes With Nephropathy
  160. Insulin in methionine and homocysteine kinetics in healthy humans: plasma vs. intracellular models
  161. Central role of PKCδ in glycoxidation-dependent apoptosis of human neurons
  162. Leptin as a Uremic Toxin Interferes with Neutrophil Chemotaxis
  163. Kidney Protein Dynamics and Ammoniagenesis in Humans with Chronic Metabolic Acidosis
  164. Testosterone promotes apoptotic damage in human renal tubular cells
  165. Oxidative Stress Mediates Apoptotic Changes Induced by Hyperglycemia in Human Tubular Kidney Cells
  166. A novel role of protein kinase C-δ in cell signaling triggered by glutathione depletion
  167. Role of PKC-δ activity in glutathione-depleted neuroblastoma cells
  168. Interorgan exchange of aminothiols in humans
  169. Role of blood cells in leucine kinetics across the human kidney
  170. Taurine Prevents Apoptosis Induced by High Ambient Glucose in Human Tubule Renal Cells
  171. Determinants of outcome in ANCA-associated glomerulonephritis: A prospective clinico-histopathological analysis of 96 patients
  172. The metabolic conversion of phenylalanine into tyrosine in the human kidney: Does it have nutritional implications in renal patients?
  173. Apoptosis Induced by Serum Withdrawal in Human Mesangial Cells
  174. Amino Acid Biosynthesis
  175. Plasma protein synthesis in patients with low-grade nephrotic proteinuria
  176. Interorgan amino acid exchange
  177. Phenylalanine hydroxylation across the kidney in humans Rapid Communication
  178. Phenylalanine hydroxylation across the kidney in humans
  179. Randomized, double-blind, placebo-controlled study of arginine supplementation in chronic renal failure
  180. Muscle amino acid metabolism and the control of muscle protein turnover in patients with chronic renal failure
  181. Noramidopyrine (Metamizol) and acute interstitial nephritis
  182. Inter-organ Leptin Exchange in Humans
  183. Effects of recombinant human growth hormone on muscle protein turnover in malnourished hemodialysis patients.
  184. Leucine Metabolism and Protein Dynamics in the Human Kidney
  185. Kidney, splanchnic, and leg protein turnover in humans. Insight from leucine and phenylalanine kinetics.
  186. Long-Term Response of Renal Function in Crescentic Membranous Glomerulonephritis after Plasma Exchange and Immunosuppressive Therapy
  187. Renal Metabolism of C-Peptide in Patients with Early Insulin-Dependent Diabetes mellitus
  188. Disposal of exogenous amino acids by muscle in patients with chronic renal failure
  189. Blood Amino Acid Levels and Erythropoietin Treatment in Hemodialysis Patients
  190. Skeletal muscle protein synthesis and degradation in patients with chronic renal failure
  191. Postanaesthetic myoglobinuric renal failure: an isolated expression of malignant hyperthermia
  192. Role of haematological, pulmonary and renal complications in the long-term prognosis of patients with lysinuric protein intolerance
  193. Erythropoietin Treatment and Amino Acid Metabolism in Hemodialysis Patients
  194. Effects of a Protein Meal on Blood Amino Acid Profile in Patients with Chronic Renal Failure
  195. Reversed-phase high-performance liquid chromatographic analysis of branched-chain keto acid hydrazone derivatives: optimization of techniques and application to branched-chain keto acid balance studies across the forearm
  196. Arteriovenous fistula of the native kidney: diagnosis by duplex Doppler ultrasound.
  197. Renal ammoniagenesis in humans with chronic potassium depletion
  198. Renal metabolism of amino acids in early insulin-dependent diabetes mellitus
  199. Effects of a new amino acid supplement on blood AA pools in patients with chronic renal failure
  200. Primary hyperoxaluria: a report of a case
  201. Acute Renal Failure Due to Acute Bilateral Renal Artery Thrombosis: Successful Surgical Revascularization after Prolonged Anuria
  202. Multiple venous sampling for catecholamine assay in the diagnosis of malignant pheochromocytoma
  203. Good Therapeutical Response of Goodpasture’s Syndrome with Severe Renal Failure
  204. Hypernatremia Associated with Severe Rhabdomyolysis
  205. Successful Treatment of Mitomycin C-Associated Hemolytic Uremic Syndrome by Plasmapheresis
  206. Splanchnic exchange of amino acids after amino acid ingestion in patients with chronic renal insufficiency
  207. Glyoxylic Acid in Ethylene Glycol Poisoning
  208. Effect of amino acid ingestion on blood amino acid profile in patients with chronic renal failure
  209. Renal Metabolism of C-Peptide in Man*
  210. Circadian monitoring of gastric juice mutagenicity
  211. Comparative effects of nonionic (iopamidol) and ionic (sodium and meglumine diatrizoate) contrast media for urography on urinary excretion of water and solutes
  212. Effects of Hemodialysis on Guanidinopropionic Acid Metabolism
  213. Leg Metabolism of Amino Acids and Ammonia in Patients with Chronic Renal Failure
  214. Renal ammoniagenesis in an early stage of metabolic acidosis in man.
  215. Brain metabolism of amino acids and ammonia in patients with chronic renal insufficiency
  216. Amino acid metabolism and the liver in renal failure
  217. Renal metabolism of amino acids and ammonia in subjects with normal renal function and in patients with chronic renal insufficiency.
  218. Study of bioassayable somatomedin on renal artery and vein
  219. Effects of Chronic Renal Insufficiency and Metabolic Acidosis on Glutamine Metabolism in Man
  220. Abnormalities in Amino Acid Metabolism in Chronic Renal Failure
  221. Abnormalities in Amino Acid Metabolism in Patients with Chronic Renal Failure
  222. Abnormalities in Amino Acid Metabolism in Patients with Chronic Renal Failure
  223. Amino Acid Imbalance in Patients with Chronic Renal Failure
  224. Determinants of the Partition of Renal Ammonia Production between Urine and Venous Blood in Man with Metabolic Acid-Base Disturbances
  225. Muscle Amino Acid and Protein Metabolism in Chronic Renal Failure
  226. Renal Ammoniagenesis in Man with Chronic Potassium Depletion
  227. Short- and Long-Term Effects of Methylprednisolone Pulses and Oral Cyclophosphamide in Renal Micropolyarteritis